9mw1911
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 29, 2021 (NCT05803902)
Timeline
Indications
Mechanism of action
- Interleukin-1 receptorANTAGONIST
IL1R1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07292714 | Phase 2 | Jul 15, 2025 | Mabwell |
| NCT06175351 | Phase 1/Phase 2 (Phase 2) | Jul 6, 2023 | Mabwell |
| NCT05170243 | Phase 1 | Jan 21, 2022 | Mabwell |
| NCT05803902 | Phase 1 | Dec 29, 2021 | Mabwell |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mabwell | For profit | 4 | 4 | 2 | 2021 |
1 organizations
Page 1 / 1